US 11,725,063 B2
Antibodies against HPA-1a
Terje Michaelsen, Hagan (NO); Oistein Ihle, Ski (NO); Tor Brynjar Stuge, Tromso (NO); Anne Husebekk, Tromso (NO); Heidi Tiller, Tromso (NO); Mariana Eksteen, Tromso (NO); and Bjorn Ragnar Skogen, Tromso (NO)
Assigned to Rallybio IPA, LLC, New Haven, CT (US)
Filed by Rallybio IPA, LLC, New Haven, CT (US)
Filed on Dec. 9, 2020, as Appl. No. 17/116,882.
Application 17/116,882 is a division of application No. 15/300,656, granted, now 10,882,919, previously published as PCT/EP2015/057102, filed on Mar. 31, 2015.
Claims priority of application No. 1405775 (GB), filed on Mar. 31, 2014; and application No. 1417614 (GB), filed on Oct. 6, 2014.
Prior Publication US 2021/0189005 A1, Jun. 24, 2021
Int. Cl. C07K 16/34 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/34 (2013.01) [C07K 16/2848 (2013.01); G01N 33/6893 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/54 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/705 (2013.01); G01N 2800/38 (2013.01)] 20 Claims
 
1. A method of treating fetal and neonatal alloimmune thrombocytopenia (FNAIT) in a fetus of a subject, the method comprising administering to the subject an effective amount of an anti-HPA-1a antibody, wherein the antibody comprises a variable region light chain (VL) comprising:
(a) a VL complementarity determining region (CDR)1 that has the amino acid sequence of SEQ ID NO: 8;
(b) a VL CDR2 that has the amino acid sequence of SEQ ID NO: 9; and
(c) a VL CDR3 that has the amino acid sequence of SEQ ID NO: 10;
and wherein the antibody comprises a variable region heavy chain (VH) comprising:
(d) a VH CDR1 that has the amino acid sequence of SEQ ID NO: 5;
(e) a VH CDR2 that has the amino acid sequence of SEQ ID NO: 6; and
(f) a VH CDR3 that has the amino acid sequence of SEQ ID NO: 7;
wherein the antibody is a full-length IgG antibody, and wherein the subject is an HPA-1a-negative woman.